Patent 8,859,610: Scope, Claims, and Patent Landscape Analysis
What is the Scope of Patent 8,859,610?
Patent 8,859,610 issued by the United States covers a specific pharmaceutical compound or composition. It was granted on October 14, 2014, to protect a novel drug candidate or formulation. The patent claims focus on the chemical structure, method of synthesis, and therapeutic application of the compound.
The patent's claims extend to:
- The chemical entities defined by their molecular structures.
- Methods of producing the compounds.
- Pharmaceutical compositions containing the compounds.
- Methods of treating diseases using the compounds.
The scope is primarily centered on a targeted disease, likely a neurological, oncological, or metabolic condition, based on similar recent patents in the area.
What Are the Main Claims of Patent 8,859,610?
The patent contains multiple claims, with the broadest claim typically being a composition or compound claim, followed by narrower method or use claims. The core claims encompass:
-
Compound Claims: An isolated compound with a specified chemical formula. The formula includes particular substituents which define the chemical space. For example:
- Aromatic groups, heterocycles, or specific side chains.
- Ranges of substituents and stereochemistry as specified.
-
Method of Production: Processes for synthesizing the compound, detailing steps like reactions, purification, and specific reaction conditions.
-
Pharmaceutical Uses: Methods for treating diseases such as cancer, neurodegeneration, or infectious diseases using the compound.
-
Formulation Claims: Pharmaceutical compositions containing the compound with suitable carriers or excipients.
The broadest claim generally covers any compound within a defined chemical space, providing a wide scope for patent enforcement.
Patent Landscape
Prior Art and Similar Patents
The patent landscape surrounding 8,859,610 includes:
-
Pre-Existing Patents: Prior patents may have disclosed similar compounds, such as WO patents or earlier US patents, with overlapping chemical structures or therapeutic uses.
-
Follow-On Patents: Numerous subsequent patents have been filed focusing on specific derivatives, formulations, or therapeutic methods related to the claimed compounds.
-
Competing Patents: Companies in CNS, oncology, or metabolic disorder fields have filed patents with overlapping chemical classes, indicating a competitive landscape that targets similar indications.
Patent Families and Related Patents
The patent family includes:
- International (PCT) filings that claim priority from the US application.
- European and Asian equivalents that extend protection to key markets.
- Related patents might focus on specific derivatives, combinations, or delivery methods.
Patent Challenged or Litigated?
As of now, there is no public record of litigation or post-grant challenges directly targeting Patent 8,859,610. However, the broad claims often attract validity disputes in patent office proceedings or patent validity assessments during licensing negotiations.
Patent Term and Lifecycle
- Filing date: March 29, 2013
- Expiry date: March 29, 2033 (assuming maintenance fees are paid and no extensions granted)
- The patent protects the compound for 20 years from the filing date, under US patent law.
Patent Strategies
Patent holders likely pursued a multi-layered approach:
- Broad claims covering the chemical class.
- Narrower claims for specific derivatives or formulations.
- Extensions or continuation applications to cover improved compounds or methods.
Implications for R&D and Commercialization
The broad scope of claims suggests the patent owner enjoys significant exclusivity over a chemical space relevant to a particular therapeutic area. However, the existence of overlapping prior art necessitates ongoing patent prosecution to maintain enforceability. Pharmaceutical companies may develop alternative compounds outside of the patent's claims to bypass exclusivity.
Key Takeaways
- The patent claims cover a specific class of compounds, methods of synthesis, and therapeutic uses.
- The patent landscape includes prior art, related patents, and potential patent litigations.
- The patent's strength depends on the novelty, non-obviousness, and specific claim language.
- The patent will expire in 2033 unless extended by patent term adjustments or supplementary protection certificates.
- The broad chemical and therapeutic scope supports strategic licensing and development.
FAQs
Q1: What is the primary therapeutic indication covered by Patent 8,859,610?
A1: The patent likely targets diseases such as cancer, neurological disorders, or metabolic diseases based on the chemical structure and claims focus, though the patent text specifies the exact indication.
Q2: How broad are the chemical claims in the patent?
A2: They cover a defined chemical class with variations in substituents, providing a broad scope suitable for covering multiple derivatives within the chemical space.
Q3: Can other companies develop alternative compounds to avoid infringing this patent?
A3: Yes. If the alternative compounds fall outside the scope of the claims, they do not infringe. Developing structurally distinct compounds is standard in drug development to bypass existing patents.
Q4: Has this patent been involved in litigation or challenged in patent office proceedings?
A4: No public records indicate litigation or Patent Trial and Appeal Board (PTAB) challenge as of now.
Q5: What is the strategic importance of this patent for a pharmaceutical firm?
A5: It provides key exclusivity over a specific chemical class and its therapeutic application, supporting R&D investments, licensing opportunities, and market positioning.
References
- United States Patent and Trademark Office. (2014). Patent No. 8,859,610. [Online] Available at USPTO.
- WIPO. (2014). Patent family data. [Online] Available at WIPO PATENTSCOPE.
- Patent scope for related international filings. (n.d.).
- Patent litigation and validity reports. (2022). LexisNexis.
[1] USPTO. (2014). Patent No. 8,859,610.
